Biogen

Company Overview

Biogen Inc. (NASDAQ: BIIB) is a Cambridge, Massachusetts-based biotechnology company founded in 1978 as Biogen S.A., making it one of the oldest biotech companies in the world. Biogen has established itself as a global leader in neuroscience, with a portfolio spanning multiple sclerosis (MS), Alzheimer's disease ([AD](/diseases/alzheimers-disease)), Parkinson's disease ([PD](/diseases/parkinsons-disease)), and rare neurological conditions.

With revenues exceeding $8 billion annually and a market capitalization of approximately $25 billion (as of 2026), Biogen operates globally with approximately 7,500 employees across 30 countries. The company's mission centers on advancing novel therapies for serious neurological and neurodegenerative diseases where there remains significant unmet medical need.

History

Founding and Early Years

Biogen was founded in 1978 in Geneva, Switzerland, by a group of European scientists including Kenneth Murray (who later won the Nobel Prize), Walter Gilbert, and Charles B. H. Weissman. The company initially focused on interferon research, establishing the scientific foundation for what would become a leading position in immunology.

The company relocated its headquarters to Boston, Massachusetts, in 1985, and conducted its initial public offering on NASDAQ in 1991. Through the 1990s and 2000s, Biogen grew through both internal development and strategic acquisitions.

Key Milestones

Company Overview

Biogen Inc. (NASDAQ: BIIB) is a Cambridge, Massachusetts-based biotechnology company founded in 1978 as Biogen S.A., making it one of the oldest biotech companies in the world. Biogen has established itself as a global leader in neuroscience, with a portfolio spanning multiple sclerosis (MS), Alzheimer's disease ([AD](/diseases/alzheimers-disease)), Parkinson's disease ([PD](/diseases/parkinsons-disease)), and rare neurological conditions.

With revenues exceeding $8 billion annually and a market capitalization of approximately $25 billion (as of 2026), Biogen operates globally with approximately 7,500 employees across 30 countries. The company's mission centers on advancing novel therapies for serious neurological and neurodegenerative diseases where there remains significant unmet medical need.

History

Founding and Early Years

Biogen was founded in 1978 in Geneva, Switzerland, by a group of European scientists including Kenneth Murray (who later won the Nobel Prize), Walter Gilbert, and Charles B. H. Weissman. The company initially focused on interferon research, establishing the scientific foundation for what would become a leading position in immunology.

The company relocated its headquarters to Boston, Massachusetts, in 1985, and conducted its initial public offering on NASDAQ in 1991. Through the 1990s and 2000s, Biogen grew through both internal development and strategic acquisitions.

Key Milestones

• 1996: Launch of AVONEX (interferon beta-1a) for multiple sclerosis
• 2003: Merger with IDEC Pharmaceuticals; acquisition of AVONEX
• 2013: Acquisition of Convergence Pharmaceuticals; expansion into pain
• 2016: Collaboration with Ionis on RNA-targeting therapies
• 2017: Launch of SPINRAZA (nusinersen) for spinal muscular atrophy
• 2020: Partnership with Denali Therapeutics on LRRK2 inhibitors
• 2021: Launch of ADUCANEMAB (Aduhelm) for Alzheimer's disease
• 2023: LEQEMBI (lecanemab) approval for early Alzheimer's

Neuroscience Portfolio

Alzheimer's Disease

Biogen's Alzheimer's disease program represents a significant focus, with two amyloid-targeting antibodies:

LEQEMBI (lecanemab)

LEQEMBI (generic: lecanemab-irmb) is a monoclonal antibody targeting amyloid-beta protofibrils, developed in partnership with Eisai. Approved by the FDA in January 2023 for treatment of early Alzheimer's disease (MCI due to AD and mild AD dementia).

• Mechanism: Binds to and removes toxic amyloid-beta protofibrils
• Dosing: Intravenous infusion every two weeks
• Efficacy: 27% slowing of clinical decline in Clarity AD trial (18 months)
• ARIA: Amyloid-related imaging abnormalities (brain edema) in ~13% of patients

Previously: ADUCANEMAB (Aduhelm)

Aducanemab was Biogen's first amyloid antibody, received accelerated approval in 2021 but was later withdrawn from the market in 2024 following commercial challenges and negative coverage policies.

Multiple Sclerosis

Biogen remains a leader in MS:

| Product | Mechanism | Launch |
|---------|-----------|-------|
| AVONEX | Interferon beta-1a | 1996 |
| TYSABRI | Natalizumab | 2004 |
| TECFIDERA | Dimethyl fumarate | 2013 |
| VUMERITY | Diroximel fumarate | 2019 |
| SKYRIZI | Risankizumab | 2019 |

Spinal Muscular Atrophy

SPINRAZA (nusinersen) was a landmark approval, demonstrating that antisense oligonucleotides could successfully modify neurological disease. Originally developed with Ionis, Biogen acquired full rights in 2018.

Parkinson's Disease Program

Biogen's Parkinson's disease pipeline includes LRRK2 inhibitors developed in partnership with Denali Therapeutics.

LRRK2 Inhibitor Partnership with Denali

Background

In June 2020, Biogen entered into a strategic partnership with Denali Therapeutics to co-develop and co-commercialize LRRK2 inhibitors for Parkinson's disease. This partnership was part of Biogen's broader strategy to expand its neuroscience franchise into movement disorders.

BIIB122 (formerly DNL151)

BIIB122 is the lead compound from this partnership, now the most clinically advanced LRRK2 inhibitor in development.

Partnership Structure:

• Biogen obtained exclusive worldwide rights to co-develop and co-commercialize BIIB122
• Denali retained option to co-promote in the US
• Joint development costs and profits shared: Biogen 70%, Denali 30%
• Denali eligible for up to $465 million in development and commercial milestones

| Trial | Phase | Population | Status |
|-------|-------|-----------|--------|
| SUNRISE | Phase 2a | LRRK2-PD | Complete |
| LUMA | Phase 2b | Idiopathic PD (n=650) | Ongoing |

Additional Programs

The partnership also includes access to Denali's Transport Vehicle (TV) platform for up to five additional CNS targets, though no specific programs have entered the clinic as of 2026.

Research Focus Areas

Biogen's internal research focuses on:

Neurodegeneration

• Tau pathology and spreading mechanisms
• Alpha-synuclein ([alpha-synuclein](/proteins/alpha-synuclein)) aggregation
• Neuroinflammation and microglia
• Mitochondrial dysfunction in neurodegeneration

Neurodevelopment

• Synapse formation and function
• Neuronal plasticity
• Myelin biology

Genetic Risk

• Target identification through human genetics
• Validation of novel pathways
• Precision medicine approaches

Clinical Development Infrastructure

Biogen maintains significant clinical development capabilities:

• Global clinical operations: 200+ active clinical sites across 40 countries
• Neuroscience focus: Deep expertise in neurodegenerative disease clinical trials
• Biomarkers: CSF, PET, and blood-based biomarker programs
• Regulatory experience: Multiple successful NDA filings

Leadership

• Christopher A. Viehbacher (CEO): Formerly Sanofi, joined 2022
• Alfred Sandrock Jr. (CMO): Neuroscientist, 20+ years at Biogen
• Catherine A. M. (CFO): Formerly Deloitte
• Rupesh V. Chaturvedi (COO): Longtime Biogen executive

Financial Overview (2025)

| Metric | Value |
|--------|-------|
| Revenue | $8.2 billion |
| Net Income | $1.1 billion |
| R&D | $2.5 billion |
| Market Cap | ~$25 billion |
| Employees | 7,500 |

Revenue Breakdown:

| Product | Revenue | Indication |
|---------|---------|-----------|
| SPINRAZA | $1.7B | SMA |
| TECFIDERA | $1.9B | MS |
| TYSABRI | $2.1B | MS |
| LEQEMBI | $0.8B | Alzheimer's |
| Other | $1.7B | Various |

Strategic Priorities (2026-2028)

References